Valuation: Axsome Therapeutics, Inc.

Market Cap 12.03B 10.55B 9.77B 8.99B 17.01B 1,152B 17.34B 116B 45.69B 565B 45.18B 44.19B 1,953B P/E 2026 *
-114x
P/E 2027 * 41.4x
Enterprise Value 11.92B 10.46B 9.68B 8.91B 16.85B 1,141B 17.18B 115B 45.27B 560B 44.76B 43.78B 1,935B EV / Sales 2026 *
12.1x
EV / Sales 2027 * 7.28x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week-6.03%
Current month-6.87%
1 month-10.04%
3 months+27.83%
6 months+30.76%
Current year+24.81%
1 week 224.7
Extreme 224.7001
252.6
1 month 224.7
Extreme 224.7001
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Fiscal year

Chief Executive Officer

148,998 0.2895%
Jun. 10Sell

Director

-286 0.0006%
Jun. 09Sell

Director

-643 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%-6.03%+102.94%+212.27% 12.03B
-0.36%+1.62%+15.73%-8.41% 67.61B
-0.63%-7.39%+36.54%+199.82% 51.6B
+0.36%+40.00%+40.00%+40.00% 43B
-1.26%-0.39%-49.63%-53.84% 40.94B
+4.70%-0.11%+56.44%-25.09% 29.4B
-2.57%-18.39%+103.10%-47.27% 27.09B
-1.36%-0.65%+64.14%+85.45% 23.32B
-0.67%+1.48%+10.61%+188.35% 19.92B
-2.12%-3.92%+56.13%+130.60% 16.91B
Average -0.61%-3.39%+43.60%+72.19% 33.18B
Weighted average by Cap. -0.39%-3.10%+33.10%+53.48%

Financials

2026 *2027 *
Net sales 981M 861M 797M 734M 1.39B 93.93B 1.41B 9.5B 3.73B 46.13B 3.69B 3.6B 159B 1.6B 1.4B 1.3B 1.19B 2.26B 153B 2.3B 15.48B 6.07B 75.14B 6B 5.87B 259B
Net income -106M -93.32M -86.44M -79.53M -150M -10.18B -153M -1.03B -404M -5B -400M -391M -17.27B 313M 275M 254M 234M 443M 29.97B 451M 3.03B 1.19B 14.72B 1.18B 1.15B 50.82B
Net Debt -111M -97.09M -89.93M -82.74M -157M -10.6B -160M -1.07B -420M -5.2B -416M -407M -17.97B -394M -345M -320M -294M -557M -37.69B -568M -3.81B -1.5B -18.51B -1.48B -1.45B -63.92B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-13 $228.57 -2.24% 449,888
26-07-10 $233.80 -6.09% 804,667
26-07-09 $248.95 +1.38% 621,739
26-07-08 $245.57 -1.68% 769,421
26-07-07 $249.76 +2.95% 1,055,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
233.80USD
Average target price
276.56USD
Spread / Average Target
+18.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock